Report #2857725

Received Sep 10, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: Age unknown
State: —
Recovered: Unknown
Vaccinated: Apr 1, 2025
Onset: Aug 1, 2025
Days to onset: 122
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	1	—	IM

Symptoms (2)

Interchange of vaccine productsNo adverse event

Symptom narrative

Received a HEPLISAV-B End of April 2025 Then Received TWINRIX; Initial report received on 20-Aug-2025. A pharmacist reported that a male patient (race and ethnicity not reported) received HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization first dose and then received TWINRIX as a second dose. No medical history or concomitant medications were reported. At the end of Apr-2025, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot#, expiration date, NDC #, route and site not available). In Aug-2025, after having been vaccinated with HEPLISAV-B, the patient received a dose of TWINRIX (no details provided) as a second dose for hepatitis B vaccination. The reporter stated that the patient had no other side effects reported. No other information was available per the reporter. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.

Other medications

Twinrix